Your browser doesn't support javascript.
loading
Bone mineral density in patients with metastatic prostate cancer with or without androgen deprivation therapy
APMC-Annals of Punjab Medical College. 2011; 5 (1): 7-14
in English | IMEMR | ID: emr-175237
Responsible library: EMRO
ABSTRACT
Prostate cancer commonly metastatize to skeletal sites. Androgen deprivation therapy [ADT], the primary treatment of metastatic prostate cancer, may result in osteoporosis. Bone mineral density evaluation during androgen deprivation therapy can detect patients at risk of osteoporotic fractures
Search on Google
Index: IMEMR (Eastern Mediterranean) Language: English Journal: Ann. Punjab Med. Coll. Year: 2011
Search on Google
Index: IMEMR (Eastern Mediterranean) Language: English Journal: Ann. Punjab Med. Coll. Year: 2011